In summary, we showed that certain subtypes of AML are particularly susceptible to NK cell-mediated antitumor immunity. The excellent therapeutic effect of the p53-activating drug in Rag2−/− mice suggest that combination of NK cell-based immunotherapy with p53-activating drug would be a promising treatment strategy for AML. Furthermore, our study highlighted the peculiar immune phenotypes of Rag2−/− mice that lack functional lymphocytes but have hyperactive NK cells.
https://www.nature.com/articles/s42003-023-05606-3
Ann: ADVENT-AML clinical trial GMP manufacturing complete, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.045M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $22.28K | 6.311M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 78 | 84735861 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 86304338 | 23 |
View Market Depth
| Last trade - 14.27pm 25/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |